Correlation between HDL2, HDL3 and serum ferritin levels with fatty liver and NAFLD activity score (NAS) in liver histology of organ donors.
Ferritin
High-density lipoprotein
Liver transplant
Nonalcoholic fatty liver disease
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
27 Oct 2021
27 Oct 2021
Historique:
received:
14
05
2021
accepted:
08
10
2021
entrez:
28
10
2021
pubmed:
29
10
2021
medline:
30
10
2021
Statut:
epublish
Résumé
Nonalcoholic fatty liver disease (NAFLD) is one of the most important liver diseases. High-density lipoprotein (HDL) has anti-atherogenic properties and its reduction can be associated with fatty liver. Serum ferritin levels are usually elevated in patients with NAFLD. This study aimed to evaluate the correlation between HDL subtypes and serum ferritin levels with evidence of NAFLD in liver histology of organ donors. One hundred organ donor patients who were eligible for the study were included in the study and ferritin; HDL2 and HDL3 were measured in blood samples. Donated liver tissue biopsy specimens were evaluated for fatty liver and NAFLD activity score (NAS). In addition, AST and ALT were measured in recipients 24 h after transplant. All data abstracted and analyzed statistically. Serum HDL2 levels and HDL2/HDL3 ratio in patients with NAS > 1 were significantly lower (P < 0.05). Serum levels of HDL3 and ferritin were not significantly associated with NAS >1 (P > 0.05). In addition, serum ferritin > 1000 ng/ml in organ donors associated with increased AST and ALT levels 24 h after transplantation in the liver organ recipient. Lower HDL2 values and HDL2/HDL3 ratio were associated with increased NAFLD activity score, but HDL3 and ferritin did not show such a relationship. In addition, higher levels of ferritin in organ donors may be associated with increased AST and ALT 24 h after liver transplantation in the organ recipient.
Sections du résumé
BACKGROUND
BACKGROUND
Nonalcoholic fatty liver disease (NAFLD) is one of the most important liver diseases. High-density lipoprotein (HDL) has anti-atherogenic properties and its reduction can be associated with fatty liver. Serum ferritin levels are usually elevated in patients with NAFLD. This study aimed to evaluate the correlation between HDL subtypes and serum ferritin levels with evidence of NAFLD in liver histology of organ donors.
METHODS
METHODS
One hundred organ donor patients who were eligible for the study were included in the study and ferritin; HDL2 and HDL3 were measured in blood samples. Donated liver tissue biopsy specimens were evaluated for fatty liver and NAFLD activity score (NAS). In addition, AST and ALT were measured in recipients 24 h after transplant. All data abstracted and analyzed statistically.
RESULTS
RESULTS
Serum HDL2 levels and HDL2/HDL3 ratio in patients with NAS > 1 were significantly lower (P < 0.05). Serum levels of HDL3 and ferritin were not significantly associated with NAS >1 (P > 0.05). In addition, serum ferritin > 1000 ng/ml in organ donors associated with increased AST and ALT levels 24 h after transplantation in the liver organ recipient.
CONCLUSIONS
CONCLUSIONS
Lower HDL2 values and HDL2/HDL3 ratio were associated with increased NAFLD activity score, but HDL3 and ferritin did not show such a relationship. In addition, higher levels of ferritin in organ donors may be associated with increased AST and ALT 24 h after liver transplantation in the organ recipient.
Identifiants
pubmed: 34706656
doi: 10.1186/s12876-021-01958-4
pii: 10.1186/s12876-021-01958-4
pmc: PMC8549218
doi:
Substances chimiques
Cholesterol, HDL
0
Lipoproteins, HDL
0
Lipoproteins, HDL2
0
Lipoproteins, HDL3
0
Ferritins
9007-73-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
405Subventions
Organisme : Vice-Chancellor for Research, Shiraz University of Medical Sciences
ID : 21083
Informations de copyright
© 2021. The Author(s).
Références
Diabetes Care. 2008 Feb;31(2):366-8
pubmed: 18000185
Arthritis Res Ther. 2012 May 14;14(3):R116
pubmed: 22584154
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Semin Liver Dis. 2001;21(1):17-26
pubmed: 11296693
Sci Rep. 2018 Aug 3;8(1):11691
pubmed: 30076407
J Hepatol. 2011 Oct;55(4):920-32
pubmed: 21718726
Dig Dis Sci. 1979 Nov;24(11):835-8
pubmed: 520102
Metabolism. 1998 Aug;47(8):965-73
pubmed: 9711993
Gastroenterol Jpn. 1983 Apr;18(2):98-108
pubmed: 6852443
Clin Liver Dis. 2004 Aug;8(3):521-33, viii
pubmed: 15331061
Gastroenterology. 2011 Jan;140(1):124-31
pubmed: 20858492
J Clin Endocrinol Metab. 2011 Jun;96(6):E958-61
pubmed: 21430023
Hepatology. 2011 Mar;53(3):810-20
pubmed: 21319198
Circulation. 1991 Jul;84(1):129-39
pubmed: 2060089
Liver Int. 2016 Nov;36(11):1688-1695
pubmed: 27064133
Liver Transpl. 2015 Nov;21(11):1419-27
pubmed: 26224663
J Hepatol. 2015 Apr;62(1 Suppl):S47-64
pubmed: 25920090
J Hepatol. 2007 Apr;46(4):549-52
pubmed: 17316880
Hepatology. 2012 Jan;55(1):77-85
pubmed: 21953442
QJM. 2012 Aug;105(8):769-74
pubmed: 22491655
Semin Liver Dis. 2001;21(1):3-16
pubmed: 11296695
Semin Liver Dis. 2012 Feb;32(1):3-13
pubmed: 22418883